Clinical trial results for a new melanoma vaccine are promising, but UNSW Sydney experts say key questions still need to be answered.
What is the difference between the mRNA vaccine and the adenovirus vaccine? Can the mRNA vaccine be tweaked when new variants develop?
Skyrocketing demand coupled with shortages of vital components is leading to bottlenecks in the supply chain of Pfizer's and other mRNA vaccines.
The best approach for protecting everyone’s health will require us to provide different vaccines to different people according to need and availability.
